Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Effect of Treatment Modalities on Progression-Free Survival and Overall Survival in Molecularly Subtyped World Health Organization Grade II Diffuse Gliomas: A Systematic Review.

Ghaffari-Rafi A, Samandouras G.

World Neurosurg. 2019 Aug 29. pii: S1878-8750(19)32267-3. doi: 10.1016/j.wneu.2019.08.111. [Epub ahead of print] Review.

PMID:
31473344
2.

Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.

Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D; For POLA Network.

Acta Neuropathol. 2016 Oct;132(4):625-34. doi: 10.1007/s00401-016-1611-8. Epub 2016 Aug 29.

PMID:
27573687
3.

Radiotherapy for diffuse brainstem glioma in children and young adults.

Hu X, Fang Y, Hui X, Jv Y, You C.

Cochrane Database Syst Rev. 2016 Jun 27;(6):CD010439. doi: 10.1002/14651858.CD010439.pub2. Review.

PMID:
27378212
4.

To treat or not to treat? A retrospective multicenter assessment of survival in patients with IDH-mutant low-grade glioma based on adjuvant treatment.

Paľa A, Coburger J, Scherer M, Ahmeti H, Roder C, Gessler F, Jungk C, Scheuerle A, Senft C, Tatagiba M, Synowitz M, Wirtz CR, Schmitz B, Unterberg AW.

J Neurosurg. 2019 Jul 19:1-8. doi: 10.3171/2019.4.JNS183395. [Epub ahead of print]

PMID:
31323633
5.

The role of surgery in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.

Aghi MK, Nahed BV, Sloan AE, Ryken TC, Kalkanis SN, Olson JJ.

J Neurooncol. 2015 Dec;125(3):503-30. doi: 10.1007/s11060-015-1867-1. Epub 2015 Nov 3. Review.

PMID:
26530265
6.

Reclassification of Mongolian Diffuse Gliomas According to the Revised 2016 World Health Organization Central Nervous System Tumor Classification.

Ochirjav E, Enkhbat B, Baldandorj T, Choe G.

J Pathol Transl Med. 2019 Sep;53(5):298-307. doi: 10.4132/jptm.2019.07.15. Epub 2019 Aug 2.

7.

Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection.

Nitta M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K, Iseki H, Tamura M, Saito T, Okamoto S, Chernov M, Hayashi M, Okada Y.

Neurosurg Focus. 2015 Jan;38(1):E7. doi: 10.3171/2014.10.FOCUS14651.

PMID:
25599276
8.

Evaluation of DNA ploidy with intraoperative flow cytometry may predict long-term survival of patients with supratentorial low-grade gliomas: Analysis of 102 cases.

Suzuki A, Maruyama T, Nitta M, Komori T, Ikuta S, Chernov M, Tamura M, Kawamata T, Muragaki Y.

Clin Neurol Neurosurg. 2018 May;168:46-53. doi: 10.1016/j.clineuro.2018.02.027. Epub 2018 Feb 21.

PMID:
29522936
9.

Updated therapeutic strategy for adult low-grade glioma stratified by resection and tumor subtype.

Nitta M, Muragaki Y, Maruyama T, Iseki H, Ikuta S, Konishi Y, Saito T, Tamura M, Chernov M, Watanabe A, Okamoto S, Maebayashi K, Mitsuhashi N, Okada Y.

Neurol Med Chir (Tokyo). 2013;53(7):447-54.

10.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
11.

IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.

Gorovets D, Kannan K, Shen R, Kastenhuber ER, Islamdoust N, Campos C, Pentsova E, Heguy A, Jhanwar SC, Mellinghoff IK, Chan TA, Huse JT.

Clin Cancer Res. 2012 May 1;18(9):2490-501. doi: 10.1158/1078-0432.CCR-11-2977. Epub 2012 Mar 13.

12.

TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.

Zhang ZY, Chan AK, Ding XJ, Qin ZY, Hong CS, Chen LC, Zhang X, Zhao FP, Wang Y, Wang Y, Zhou LF, Zhuang Z, Ng HK, Yan H, Yao Y, Mao Y.

Oncotarget. 2015 Sep 22;6(28):24871-83. doi: 10.18632/oncotarget.4549.

13.

Prognostic Value of O-(2-[18F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma.

Kertels O, Kessler AF, Mihovilovic MI, Stolzenburg A, Linsenmann T, Samnick S, Brändlein S, Monoranu CM, Ernestus RI, Buck AK, Löhr M, Lapa C.

Mol Imaging Biol. 2019 Apr 11. doi: 10.1007/s11307-019-01357-y. [Epub ahead of print]

PMID:
30977078
14.

Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.

Youland RS, Schomas DA, Brown PD, Nwachukwu C, Buckner JC, Giannini C, Parney IF, Laack NN.

Neuro Oncol. 2013 Aug;15(8):1102-10. doi: 10.1093/neuonc/not080. Epub 2013 Jun 27.

15.

A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation.

Ho CY, Mobley BC, Gordish-Dressman H, VandenBussche CJ, Mason GE, Bornhorst M, Esbenshade AJ, Tehrani M, Orr BA, LaFrance DR, Devaney JM, Meltzer BW, Hofherr SE, Burger PC, Packer RJ, Rodriguez FJ.

Acta Neuropathol. 2015 Oct;130(4):575-85. doi: 10.1007/s00401-015-1467-3. Epub 2015 Aug 12.

PMID:
26264609
16.

Novel, improved grading system(s) for IDH-mutant astrocytic gliomas.

Shirahata M, Ono T, Stichel D, Schrimpf D, Reuss DE, Sahm F, Koelsche C, Wefers A, Reinhardt A, Huang K, Sievers P, Shimizu H, Nanjo H, Kobayashi Y, Miyake Y, Suzuki T, Adachi JI, Mishima K, Sasaki A, Nishikawa R, Bewerunge-Hudler M, Ryzhova M, Absalyamova O, Golanov A, Sinn P, Platten M, Jungk C, Winkler F, Wick A, Hänggi D, Unterberg A, Pfister SM, Jones DTW, van den Bent M, Hegi M, French P, Baumert BG, Stupp R, Gorlia T, Weller M, Capper D, Korshunov A, Herold-Mende C, Wick W, Louis DN, von Deimling A.

Acta Neuropathol. 2018 Jul;136(1):153-166. doi: 10.1007/s00401-018-1849-4. Epub 2018 Apr 23.

PMID:
29687258
17.

Clinical outcome of surgically treated low-grade gliomas: a retrospective analysis of a single institute.

Turkoglu E, Gurer B, Sanli AM, Dolgun H, Gurses L, Oral NA, Donmez T, Sekerci Z.

Clin Neurol Neurosurg. 2013 Dec;115(12):2508-13. doi: 10.1016/j.clineuro.2013.10.010. Epub 2013 Oct 25.

PMID:
24225484
18.

Molecular markers in low-grade gliomas: predictive or prognostic?

Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M; German Glioma Network.

Clin Cancer Res. 2011 Jul 1;17(13):4588-99. doi: 10.1158/1078-0432.CCR-10-3194. Epub 2011 May 10.

19.

Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.

Compes P, Tabouret E, Etcheverry A, Colin C, Appay R, Cordier N, Mosser J, Chinot O, Delingette H, Girard N, Dufour H, Metellus P, Figarella-Branger D.

J Neurooncol. 2019 May;142(3):511-520. doi: 10.1007/s11060-019-03122-1. Epub 2019 Feb 11. Erratum in: J Neurooncol. 2019 Mar 11;:.

PMID:
30756272
20.

Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.

Morshed RA, Han SJ, Hervey-Jumper SL, Pekmezci M, Troncon I, Chang SM, Butowski NA, Berger MS.

J Neurooncol. 2019 Jan;141(2):383-391. doi: 10.1007/s11060-018-03044-4. Epub 2018 Nov 29.

PMID:
30498891

Supplemental Content

Support Center